$INGN (Inogen, Inc.)

$INGN {{ '2016-03-14T20:40:04+0000' | timeago}} • Announcement

$INGN expects 2016 revenue to be in the range of $187-191MM, representing YoverY growth of 17.6-20.1% and adjusted net income is expected to be $12-14MM, representing 19.8-39.8% growth vs. 2015. For 2016, net income is expected to $12-14 million, representing 3.6-20.8% growth vs. 2015 and adjusted EBITDA is expected to be $37-39MM.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$KAMN {{ '2018-01-16T17:22:14+0000' | timeago}} • Announcement

$KAMN said its Aerospace segment received a contract modification in excess of $17MM for the procurement of Joint Programmable Fuzes. The award is an additional order under Option 13 of the JPF contract with the US Air Force. The modification increases the total value of Option 13 to more than $102MM, all of which was in backlog at Dec. 31, 2017.

$KAMN {{ '2018-01-10T19:21:07+0000' | timeago}} • Announcement

$KAMN announced that Rebecca F. Stath has been appointed to serve as Assistant Vice President, SEC Compliance and External Reporting, reporting to John J. Tedone, Vice President, Finance and Chief Accounting Officer.

$KAMN {{ '2018-01-10T19:16:01+0000' | timeago}} • Announcement

$KAMN announced that Amanda N. Balboni has been appointed to serve as Assistant Vice President, Internal Audit. Ms. Balboni has previously worked at Coburn Technologies, Stanley Black & Decker and PricewaterhouseCoopers.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$PII {{ '2018-01-09T19:13:23+0000' | timeago}} • Announcement

$PII named Lucy Clark Dougherty as its SVP, General Counsel, Compliance Officer and Corporate Secretary, reporting to Chairman and CEO Scott Wine effective Jan. 29, 2018. Dougherty will also serve as president of the Polaris Foundation.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AIT {{ '2018-01-09T14:46:20+0000' | timeago}} • Announcement

$AIT has agreed to acquire FCX Performance, Inc. for approx. $768MM. The deal is expected to close within 30 days. The acquisition is expected to contribute about $550MM in sales and $68MM in EBITDA in the first 12 months of applied ownership. The deal is expected to be accretive in FY19 after recognition of one-time transaction costs in FY18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$MSA {{ '2017-12-14T15:07:35+0000' | timeago}} • Announcement

$MSA's BoD has elected Nishan J. Vartanian as a director of the company. Mr. Vartanian currently serves as President and COO. His election is part of a planned management succession, and coincides with an announcement made by Chairman and CEO William M. Lambert that he intends to retire as CEO in May of 2018.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$IVC {{ '2017-12-08T13:18:08+0000' | timeago}} • Announcement

$IVC announced a reduction in force in North America that is expected to generate approx. $8.5MM in annualized pretax savings. The company expects to incur total restructuring charges in 4Q17 of approx. $2.6MM on a pretax basis, principally in the NA/HME segment and to a lesser extent in the Institutional Products Group segment.

$JCI {{ '2017-12-07T17:40:30+0000' | timeago}} • Announcement

$JCI's BoD approved an incremental $1Bil increase to its share repurchase authorization. The company has about $200MM of availability under its previously announced $1Bil share repurchase authorization.

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
INGN (Inogen, Inc.)
Tuesday, November 7 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
KAMN (Kaman Corporation)
Friday, October 27 2017 - 12:30pm
MTRN (Materion Corporation)
Thursday, October 26 2017 - 1:00pm
AIT (Applied Industrial Technologies, Inc.)
Wednesday, October 25 2017 - 2:00pm
EW (Edwards Lifesciences Corp.)
Tuesday, October 24 2017 - 9:00pm
PII (Polaris Industries Inc.)
Tuesday, October 24 2017 - 2:00pm
MSA (MSA Safety Incorporated)
Friday, October 20 2017 - 12:30pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
AIT (Applied Industrial Technologies, Inc.)
Friday, August 11 2017 - 2:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm

AlphaGraphics you may like